Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy)
Year: 2021
Type: article
Abstract: Improved understanding of tumor immunology has enabled the development of therapies that harness the immune system and prevent immune escape. Numerous clinical trials and real-world experience has provided evidence of the potential for long-term survival with immunotherapy in various types of malignancy. Recurring observations with immuno-oncology agents include their potential for clinical application across a broad patient population with different tumor types, conventional and unconventional response patterns, durable responses, and immune-related adverse events. Despite the substantial achievements to date, a significant proportion of patients still fail to benefit from current immunotherapy options, and ongoing research is focused on transforming non-responders to responders through the development of novel treatments, new strategies to combination therapy, adjuvant and neoadjuvant approaches, and the identification of biomarkers of response. These topics were the focus of the virtual Immunotherapy Bridge (December 2nd-3rd, 2020), organized by the Fondazione Melanoma Onlus, Naples, Italy, in collaboration with the Society for Immunotherapy of Cancer and are summarised in this report.
Authors: Paolo A. Ascierto, Carlo Bifulco, Fortunato Ciardiello, Sandra Demaria, Leisha A. Emens, Robert Ferris, Silvia C. Formenti, Jerome Galon, Samir N. Khleif, Tomas Kirchhoff, Jennifer McQuade, Kunle Odunsi, Akash Patnaik, Chrystal M. Paulos, Janis M. Taube, John Timmerman, Bernard A. Fox, Patrick Hwu, Igor Puzanov
Institutions: Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", University of Campania "Luigi Vanvitelli", Weill Cornell Medicine, Magee-Womens Hospital, UPMC Hillman Cancer Center, Cornell University, Inserm, Université Paris Cité, Sorbonne Université, Centre de Recherche des Cordeliers, La Ligue Contre le Cancer, Laboratoire d’immunologie intégrative du cancer, Georgetown University, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, The University of Texas MD Anderson Cancer Center, University of Chicago, University of Chicago Medicine Comprehensive Cancer Center, Winship Cancer Institute, Johns Hopkins University, University of California, Los Angeles, Ronald Reagan UCLA Medical Center, UCLA Medical Center, Providence Portland Medical Center, Moffitt Cancer Center, Roswell Park Comprehensive Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,990
OpenAlex ID: W3165836611